

# A-385358

**Catalog No: tcsc0006108**



## Available Sizes

---

**Size:** 5mg

**Size:** 10mg

**Size:** 25mg

**Size:** 50mg

**Size:** 100mg



## Specifications

---

**CAS No:**

406228-55-5

**Formula:**

$C_{32}H_{41}N_5O_5S_2$

**Pathway:**

Apoptosis

**Target:**

Bcl-2 Family

**Purity / Grade:**

>98%

**Solubility:**

DMSO : 125 mg/mL (195.36 mM; Need ultrasonic and warming)

**Observed Molecular Weight:**

639.83


## Product Description

A-385358 is a selective inhibitor of **Bcl-X<sub>L</sub>** with **K<sub>i</sub>s** of 0.80 and 67 nM for **Bcl-X<sub>L</sub>** and **Bcl-2**, respectively.

IC50 & Target: Ki: 0.80 nM (Bcl-X<sub>L</sub>), 67 nM (Bcl-2)

**In Vitro:** A-385358 is a selective inhibitor of Bcl-X<sub>L</sub> with K<sub>i</sub>s of 0.80 and 67 nM for Bcl-X<sub>L</sub> and Bcl-2, respectively, in fluorescence polarization assays. Treatment of IL-3-deprived FL5.12/Bcl-X<sub>L</sub> cells for 24 hours with A-385358 results in cell killing with an EC<sub>50</sub> of 0.47±0.05 μM (n=68). This effect is accompanied by an increase in caspase-3 activity. Consistent with the greater affinity for the Bcl-X<sub>L</sub> versus Bcl-2 hydrophobic grooves, the EC<sub>50</sub> of A-385358 for IL-3-depleted FL5.12/Bcl-2 cells (1.9±0.1 μM; n=55) is 4-fold higher relative to the cytokine-deprived FL5.12/Bcl-X<sub>L</sub> cells. In addition, A-385358 is more effective at stimulating cytochrome c release from mitochondria isolated from FL5.12/Bcl-X<sub>L</sub> versus Bcl-2 cells<sup>[1]</sup>.

**In Vivo:** The combination of A-385358 given at 100 mg/kg/d plus the lower dose of paclitaxel produces a significant reduction in tumor growth (%T/C) compare with paclitaxel monotherapy. This combination also yields a >100% increase in time for tumors to reach 900 mm<sup>3</sup> (%ILS) compare with vehicle control. Maximal efficacy is observed during the dosing period for A-385358, with slow but steady increase in the tumor growth after termination of treatment. The combination of A-385358 at 75 mg/kg/d plus paclitaxel at 30 mg/kg/d is also well tolerated and inhibits tumor growth rate by nearly 80%. Significant effects on tumor growth relative to paclitaxel monotherapy are observed with doses as low as 50 mg/kg/d<sup>[1]</sup>.



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!